SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Processing

Read more breaking news

 

 

India plans $37m investment in vaccine cGMP compliance

By Nick Taylor , 02-May-2012
Last updated on 02-May-2012 at 16:06 GMT

India plans $37m investment in vaccine cGMP compliance

The Indian government is to invest more than $37m to bring vaccine manufacturing plants in line with cGMPs.

Proposed upgrades at the plants in Chennai and Coonoor come four years after the Drug Controller General of India (DCGI) suspended licenses at three production units. The actions led to shortages of some vaccines and the government is now upgrading to boost capacity.

Approval has been obtained for upgradation of DPT group of vaccine manufacturing facilities at Coonoor with an estimated cost of Rs 137 crore ($26m) plus project management consultancy fees”, Indian health minister Shri Ghulam Nabi Azad said.

Azad revealed the DPT (diphtheria, pertussis and tetanus) plant details in reply to questioning in parliament about the compliance of Indian vaccine production facilities with cGMPs (current good manufacturing practices).

Suspension of licenses at vaccine plants in Chennai, Coonoor, and Kasauli in 2008 led to the shortage of some products and sparked outcry in India. Azad overturned the suspension and is now investing in the plants.

Upgrades costing Rs 58 crore are planned to revive a bacillus calmette-guérin (BCG) vaccine plant in Chennai. The site was also hit by the DCGI in 2008 and, although Azad said a vaccine shortage was averted, the Indian government still wants to boost its output.

Work at the third plant targeted by the DCGI, DPT vaccine production facilities in Kasauli, is nearing completion, Azad said. Last   month   Rediff   reported that HLL, a company best known for producing condoms, was handling the upgrades at all three manufacturing facilities.

L C Goyal, additional secretary, Ministry of Health, said: "We faced a shortage of vaccines when these plants got shut and hence realised the importance of expanding our capacities in vaccine manufacturing. HLL was chosen to revamp these facilities.”

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions